Literature DB >> 10533699

Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.

Y Merlé1, F Mentré.   

Abstract

Sampling times for Bayesian estimation of the pharmacokinetic parameters of an antidepressant drug, nortriptyline, during its therapeutic drug monitoring were optimized. Our attention was focused on designs including a limited number of measurements: one, two, and three sample designs in which sampling times had to be chosen between 0 and 24 hr after the last intake of a test-dose study. The optimization was conducted in four groups of patients defined by their gender and the administration or not of concomitant drugs inhibiting the metabolism of nortriptyline. The Bayesian design criterion was defined as the expected information provided by an experiment. A stochastic approximation algorithm, the Kiefer-Wolfowitz algorithm, was used for the criterion maximization under experimental constraints. Results showed that optimal Bayesian sampling times differ between patients in monotherapy and polytherapy. For one-sample designs the measurements have to be performed either at the lower (0 hr) or at the upper (24 hr) bound of the admissible interval. Replications were often found for 2- and 3-point designs. Other sampling designs can lead to criterion close to the optimum and can therefore be performed without great loss of information. In contrast, we found that several designs lead to low values of the information criterion, which justifies the approach.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10533699     DOI: 10.1023/a:1020634813296

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  14 in total

1.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

Authors:  D Z D'Argenio
Journal:  Math Biosci       Date:  1990-04       Impact factor: 2.144

2.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.

Authors:  E Steiner; L Bertilsson; J Säwe; I Bertling; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1988-10       Impact factor: 6.875

3.  Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.

Authors:  Y Merlé; F Mentré
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

Review 4.  Pharmacokinetic and pharmacodynamic data and models in clinical trials.

Authors:  J L Steimer; M E Ebelin; J Van Bree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

Review 5.  Genetically variable metabolism of antidepressants and neuroleptic drugs in man.

Authors:  M L Dahl; L Bertilsson
Journal:  Pharmacogenetics       Date:  1993-04

6.  Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.

Authors:  M L Dahl; L Bertilsson; C Nordin
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

7.  Clinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patients.

Authors:  B Miljković; M Pokrajac; I Timotijević; V Varagić
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jul-Sep       Impact factor: 2.441

8.  Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria.

Authors:  M Tod; J M Rocchisani
Journal:  Comput Methods Programs Biomed       Date:  1996-06       Impact factor: 5.428

9.  Relationship between plasma level and therapeutic effect of nortriptyline.

Authors:  M Asberg; B Crönholm; F Sjöqvist; D Tuck
Journal:  Br Med J       Date:  1971-08-07

10.  Clinical relevance of serum nortriptyline and 10-hydroxy-nortriptyline measurements in the depressed elderly: a multicenter pharmacokinetic and pharmacodynamic study.

Authors:  N M Kin; N Klitgaard; N P Nair; M Amin; P Kragh-Sorensen; G Schwariz; S K Ahmed; P Holm; C Katona; K Stage
Journal:  Neuropsychopharmacology       Date:  1996-07       Impact factor: 7.853

View more
  5 in total

1.  Pharmacokinetic variability and therapeutic drug monitoring actions at steady state.

Authors:  M Ramanathan
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

2.  Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.

Authors:  Thi Huyen Tram Nguyen; Thu Thuy Nguyen; France Mentré
Journal:  Pharm Res       Date:  2017-06-28       Impact factor: 4.200

3.  Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients.

Authors:  Carolina Consuelo Llanos-Paez; Christine Staatz; Stefanie Hennig
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

4.  Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

Authors:  Yanhua Gao; Stefanie Hennig; Michael Barras
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

5.  Inter occasion variability in individual optimal design.

Authors:  Anders N Kristoffersson; Lena E Friberg; Joakim Nyberg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-10-01       Impact factor: 2.745

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.